Top

Summer 2013 : Ibrutinib proves strong defense against mantle cell lymphoma

Ibrutinib proves strong defense against mantle cell lymphoma

Latest results confirm high rate of response, remission

In a major international study led by MD Anderson researchers, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

The most recent interim findings of the 18-center Phase II study were published in June in the New England Journal of Medicine.

“This oral inhibitor of the Bruton’s tyrosine kinase in the B-cell receptor pathway is the most important breakthrough to date in the treatment of mantle cell lymphoma,” says Michael Wang, M.D., associate professor, Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy. Wang is lead author of the trial.

“It’s an oral drug, taken once a day, and its side effects are not severe. Yet it can achieve more than previous combination chemotherapy approaches,” says Wang. “Our results constitute excellent news for patients around the world.”

Pharmacyclics, Inc., which developed ibrutinib, sponsored the clinical trial.

“It’s an oral drug, taken once a day, and its side effects are not severe. Yet it can achieve more than previous combination chemotherapy approaches. Our results constitute excellent news for patients around the world.”

Michael Wang, M.D.

associate professor, Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy

More Stories From Promise

A message from Dr. DePinho

A word from the president

Lyda Hill commits $50 million to Moon Shots Program

Cancer Prevention Center to be named in honor of Dallas philanthropist

Moon Shots Program

How team science aims to beat cancer

Private philanthropy boosts MD Anderson's Moon Shots Program

Donor commitments to unprecedented assault on cancer surpass $100 million

The medium and the message

e-Health is no longer a wave of the future - it's our reality

Tony's Prostate Cancer Research Foundation

Offering hope for a noninvasive cure

Survivors Say

Tom Bates is co-owner of Glendarroch Homes. A graduate of Texas Christian University, he lives with his wife and four children in Fort Worth.

iPromise

Ashley Loeffler, of Houston, is chair of MD Anderson's Advance Team, a volunteer leadership board of "next generation" community and business leaders. She's worked in the office of Texas Gov. George W. Bush and Sen. Jeffrey Wentworth, in the development office at The University of Texas at Austin and as campaign finance director of Texas Lt. Gov. David Dewhurst. She and her husband Lance have three children.

Music video goes viral

Martin High School contributes to first pediatric colon cancer clinical trial

A rose like no other

The Dr. Marnie Rose Foundation celebrates a decade of funding brain cancer research

No lump, still cancer

IBC survivor dedicated to fighting rare form of breast cancer

Under the Palms and on the Prairie

Polo events prove effective fundraisers in fight against cancer

Run broadens scope of awareness

Screening, education offer hope for colorectal cancer

MD Anderson's top nursing honor

Colleen Villamin claims 2013 Ethel Fleming Arceneaux Award

A generational thing

Scurlock Foundation continues tradition of making a difference

Brothers in beards

Septembeard urges men to 'be a hero' in fight against prostate cancer

Kick the butts

MD Anderson delivers anti-smoking message to students

Children's Cancer Hospital re-opening

The MD Anderson Children's Cancer Hospital's newly renovated and expanded floor space brings together all pediatric treatment and services on one floor along with Ronald McDonald Family Room areas, an in-hospital school, a large play park, a kitchen, a teen room and other amenities.

Imaging pioneer takes on leadership roles

MD Anderson team member, physician-scientist David Piwnica-Worms, M.D., Ph.D., has assumed two leadership posts at MD Anderson: chair of Cancer Systems Imaging and deputy division head, research affairs, for Diagnostic Imaging.

MD Anderson welcomes new vice provost, science

Helen Piwnica-Worms, Ph.D., has joined MD Anderson as vice provost to lead science research at the institution.

New provost, executive vice president arrives from Dartmouth

MD Anderson welcomed Ethan Dmitrovsky, M.D., in July as new provost and executive vice president.

American Cancer Society honors Isaiah J. Fidler

Medal of honor goes to pioneer and leader in cancer metastasis

Mendelsohn elected to American Academy of Arts and Sciences

John Mendelsohn, M.D., director of MD Anderson's Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and former MD Anderson president, has been elected as a fellow of the American Academy of Arts and Sciences.